摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-(S)-2-[1-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene]-4-[(1R,2R)-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]-6-methylmorpholin-3-one | 937398-67-9

中文名称
——
中文别名
——
英文名称
(Z)-(S)-2-[1-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene]-4-[(1R,2R)-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]-6-methylmorpholin-3-one
英文别名
(2Z,6S)-2-[[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-[(1R,2R)-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]-6-methylmorpholin-3-one
(Z)-(S)-2-[1-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene]-4-[(1R,2R)-2-hydroxy-1-(3,4,5-trifluorophenyl)propyl]-6-methylmorpholin-3-one化学式
CAS
937398-67-9
化学式
C25H23F4N3O3
mdl
——
分子量
489.47
InChiKey
PHIXULPHNBAFBO-UCCHRPHFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    35
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    67.6
  • 氢给体数:
    1
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Morpholine type cinnamide compound
    申请人:Kimura Teiji
    公开号:US20070117798A1
    公开(公告)日:2007-05-24
    The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X 1 represents a C1-6 alkylene group that may be substituted; X a represents a methoxy group or a fluorine atom; X b represents an oxygen atom or a methylene group, provided that X b is only an oxygen atom when X a is a methoxy group; and Ar 1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.
    本发明涉及一种由式(I)表示的化合物或其药理学上可接受的盐,其中R1、R2、R3和R4相同或不同,并且每个代表氢原子或C1-6烷基基团;X1代表可能被取代的C1-6烷基基团;Xa代表甲氧基团或原子;Xb代表氧原子或亚甲基基团,前提是当Xa为甲氧基团时,Xb仅为氧原子;Ar1代表可能具有卤素原子等取代基的芳基、吡啶基、芳氧基或吡啶氧基;以及将该化合物或盐用作药物剂的用途。
  • MORPHOLINE TYPE CINNAMIDE COMPOUND
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP1953154A1
    公开(公告)日:2008-08-06
    The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R1, R2, R3, and R4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X1 represents a C1-6 alkylene group that may be substituted; Xa represents a methoxy group or a fluorine atom; Xb represents an oxygen atom or a methylene group, provided that Xb is only an oxygen atom when Xa is a methoxy group; and Ar1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.
    本发明涉及一种由式 (I) 代表的化合物: 或其药理上可接受的盐,其中 R1、R2、R3 和 R4 相同或不同,且各自代表氢原子或 C1-6 烷基;X1 代表可被取代的 C1-6 亚烷基;Xa 代表甲氧基或原子;Xb代表氧原子或亚甲基,但当Xa为甲氧基时,Xb仅为氧原子;Ar1代表芳基、吡啶基、芳氧基或吡啶氧基,可具有卤素原子等取代基;以及将化合物或盐用作药剂。
  • PRODRUG OF CINNAMIDE COMPOUND
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP2048143A1
    公开(公告)日:2009-04-15
    Disclosed is an optimal prodrug of a cinnamide compound represented by Formula (I) below. In the formula, Ra and Rb respectively represent a C1-6 alkyl group or the like; Xa represents a methoxy group or a fluorine atom; Y represents a phosphono group or the like; and A represents a cyclic lactam derivative.
    本发明公开了下式(I)所代表的肉桂酰胺化合物的最佳原药。 式中,Ra 和 Rb 分别代表 C1-6 烷基或类似基团;Xa 代表甲氧基或原子;Y 代表膦酰基或类似基团;A 代表环内酰胺衍生物
  • US7618960B2
    申请人:——
    公开号:US7618960B2
    公开(公告)日:2009-11-17
  • US7737141B2
    申请人:——
    公开号:US7737141B2
    公开(公告)日:2010-06-15
查看更多